Patients without Mavacamten, no reimbursement
Mavacamten is an innovative drug that represents a concrete and immediate hope and an alternative to surgery for many patients ...
An international network against rare diseases
Be careful not to consider rare diseases as marginal. This is the risk that, according to Professor Giuseppe Limongelli, director of the Diseases Unit ...
Research and training, the Milan group
Communication and support to patients were the first commitment of the Milanese volunteers. Then the investigation into the management of the ...
Innovative surgical therapies for all patients
The course on Hypertrophic Obstructive Cardiomyopathy, organized by AICARM Aps, saw the participation of the best Italian specialists. Surgery ...
Anticoagulants and antiaggregants in pregnancy
In women with different types of cardiomyopathy and taking antiplatelet or anticoagulant drugs, there is a risk of maternal hemorrhages ...
My experience in San Diego where new therapies are explored
The first gene therapy for an inherited heart disease has been developed at the University of California San Diego (UCSD): the ...
Myectomy and mitral plastic surgery, the most effective therapy for young patients
The Hypertrophic Obstructive Cardiomyopathy Treatment Course is designed to present the impact of obstruction on quality of life and ...
Gene therapy for hypertrophic cardiomyopathy, what's new
Cardiomyopathies are a group of diseases that affect the heart muscle, causing impaired heart muscle function and also ...
Risk assessment of beta-blockers in pregnant women with cardiomyopathy
Therapy during pregnancy involves the use of various drugs including the beta-blocker family, used in the treatment of some ...
Comment on the genetic survey (published in the March 2024 Newsletter)
We publish the commentary of Dr. Francesca Torricelli, geneticist and former director of the Genetic Diagnostic Unit of the Careggi University Hospital, regarding ...